Skip to content
Research Article Open access CC BY 4.0

A Case Report of Severe Hypovolemic Hyponatremia Secondary to Angiotensin Receptor Blocker- thiazide Diuretic Usage

Mohammed Ziauddin, Mohammed Zabeer Uddin, Ummay Mariya, Tarannum Fatima

Asian Journal of Cardiology Research · pp. 533–537 · Published 1 Sep 2025

10.9734/ajcr/2025/v8i1310

Abstract

Key Clinical Message: Telmisartan-hydrochlorthiazide is a US FDA and CDSCO approved oral Fixed Dose combination of ARB & Diuretic for treating hypertension as second line therapy. Telmisartan is an ARBs prevent angiotensin II acting on AT1 receptors and are similar to ACEIs, but have no effect on bradykinin and do not cause cough or bradykinin-related anaphylaxis. We describe a case report of 59-Year-old female who developed severe hyponatremia following the recent administration of Telmisartan-hydrochlorthiazide Combination. Clinical and laboratory evaluations suggest severe Hypovolemic Hyponatremia, likely secondary to Angiotensin receptor blocker-thiazide diuretic. The potential side effects of this Fixed Dose Combination medication requires regular monitoring, patient education.

Hyponatremia Telmisartan-hydrochlorthiazide ARB-Angiotensin Receptor Blocker

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.